key: cord-1004000-hkxexvjb
authors: Moran, Angelica; Beavis, Kathleen G.; Matushek, Scott M.; Ciaglia, Carol; Francois, Nina; Tesic, Vera; Love, Nedra
title: Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays
date: 2020-07-23
journal: J Clin Microbiol
DOI: 10.1128/jcm.00772-20
sha: 87861244dd407e13d4477bb8c856533f7d368d41
doc_id: 1004000
cord_uid: hkxexvjb

SARS-CoV-2, a novel coronavirus responsible for a December 2019 outbreak in Wuhan, China, causes a syndrome characterized by fever, cough, and dyspnea progressing to acute respiratory distress syndrome (1).….

a mutation prevents primer binding. The Cepheid assay is a 45-min random-access assay, with throughput dependent on the number of instrument slots. The Roche platform is batch based, accommodating 90 samples/run every 90 min. As each run requires up to 3 h and 45 min, throughput is approximately 1 result per minute. Overall, the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays show excellent agreement (Ͼ99%), and their combined usage can be tailored to maximize SARS-CoV-2 testing.

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea

Washington State 2019-nCoV Case Investigation Team. 2020. First case of 2019 novel coronavirus in the United States

Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China

Presumed asymptomatic carrier transmission of COVID-19

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis

Roche Molecular Systems. 2020. cobas SARS-CoV-2. (Package insert.) US Food and Drug Administration

Xpert Xpress SARS-CoV-2. (Package insert.) US Food and Drug Administration